Form 4: Alexander Denner Reports Changes in Ironwood Pharmaceuticals Ownership

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported changes in beneficial ownership of Class A Common Stock, including the acquisition of shares and indirect ownership through Sarissa Capital Management LP.

Summary

• On December 16, 2024, Alexander Denner reported changes in his beneficial ownership of Ironwood Pharmaceuticals Inc. Class A Common Stock.
• He acquired 4,249 shares at $0 per share, issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
• Following the transaction, Denner directly owns 156,353 shares.
• Denner also indirectly owns 16,390,000 shares through Sarissa Capital Management LP and related funds.
• Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting changes in stock ownership. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in publicly traded companies. It provides transparency to the market regarding the holdings and transactions of key individuals and entities associated with Ironwood Pharmaceuticals.

Stakeholder Impact

• The change in ownership may be of interest to shareholders, as it provides insight into the actions of a major shareholder and director.

Key Dates